Telangiectatic osteosarcoma is a rare high-grade malignant neoplasm, accounting for less than 4% of all cases of osteosarcoma. It is a rare variant of osteosarcoma characterized by distinctive radiographic, gross, and microscopic features. It is a bone-forming tumor which mimics radiologically and microscopically aneurysmal bone cyst.
The exact etiology of telangiectatic osteosarcoma is still unknown, and so are the predisposing factors. However, some anecdotal reports described genetic component due to the presence of the disease in family members.
The mean age at presentation of telangiectatic osteosarcoma is 17.5 years (range: 15 to 20 years) with a male to female ratio of 2 to 1. The distal femoral metaphysis is the single most common anatomic site (42%) followed by the proximal tibia (17%), the proximal humerus (9%) and the proximal femur (8%). Uncommon sites of telangiectatic osteosarcoma include the scapula, the ribs, the sternum, the innominate bone, the cranial vault, and the mandible. Telangiectatic osteosarcoma of the spine represents 2% of all cases of primary vertebral osteosarcomas. Extra-osseous telangiectatic osteosarcoma is rare with telangiectatic osteosarcoma arising in the soft tissues of the thigh, the forearm, and popliteal fossa.
Telangiectatic osteosarcoma is presumed to derive from either transformed osteoblasts or stem cells of mesenchymal origin. Angiosarcomatous features present in addition to osteoblast-like and fibroblast-like cells at the ultrastructural level. Tight intercellular junctions, Weibel-Palade bodies, and pinocytic vesicles are visible within the cell cytoplasm. These features suggest that telangiectatic osteosarcoma derives from multipotential stem cells of mesenchymal origin.
Only seven cases of telangiectatic osteosarcoma to date to date have had genetic studies. Cytogenetic analysis identified trisomy 3 in one case, and in three other tumors, more complex chromosomal changes were reported. Metaphase CGH identified an average of 2.5 aberrations in two telangiectatic osteosarcomas and array CGH identified only three regional gains at 1q21-23.2, 1q25.2-31.1, and 7q21.13-21.2 in one tumor. This suggests that telangiectatic tumors are genetically less complex than conventional osteosarcoma.
The resected surgical specimens of telangiectatic osteosarcoma must undergo meticulous sampling. The complete face of the bone must be sampled to document the percentages of viable and necrotic tumor.
Macroscopic examination reveals a hemorrhagic multicystic lesion filled with blood clots. Telangiectatic osteosarcomas have the classic description as ''a bag of blood.'' They are, by definition composed of approximately 90% cystic components before treatment. A fleshy sarcomatous component is typically not present. The cystic spaces can vary considerably in size and may occasionally measure several centimeters in diameter. More often, there is a mixture of large cystic and spongy areas. The spongy areas represent tissue honeycombed with smaller cysts that measure up to several millimeters in size. The borders of the lesion are usually well demarcated, but often there are features of invasive growth with extensive irregular cortical erosion, complete disruption of cortical continuity, and invasion of soft tissue.
Histologically, telangiectatic osteosarcoma is composed of blood-filled or empty cystic spaces resembling aneurysmal bone cyst. The septa are populated by pleomorphic cells with important nuclear hyperchromasia and also contain osteoclast-like giant cells. Osteoid formation is usually focal and confluent. Because telangiectatic osteosarcoma is sometimes not adequately sampled by core-needle biopsy due to its lytic and cystic nature, cellular atypia and osteoid formation may be absent, which may lead to misdiagnosis. Misdiagnoses often delay accurate diagnoses and appropriate treatments, which may negatively influence patient prognosis.
No immunohistochemical studies are useful in the diagnosis of telangiectatic osteosarcoma.
There is no difference in the clinical presentation of telangiectatic and conventional osteosarcoma. Local pain and/or soft tissue mass are the most common symptoms of telangiectatic osteosarcoma. Sometimes, the patients may present with a pathologic fracture. Occasionally, a vascular bruit may be heard over the tumor.
Several imaging modalities are available for establishing the diagnosis of telangiectatic osteosarcoma. They include:
Telangiectatic osteosarcoma is typically a purely lytic lesion with a permeative destructive growth pattern. This rapidly growing tumor often expands the contour of bone and shows features of cortical disruption with minimal or no periosteal new bone formation. The massive expansile growth pattern of telangiectatic osteosarcoma can superficially simulate aneurysmal bone cyst. Telangiectatic osteosarcoma can have a deceptively innocent radiographic appearance with sharply demarcated margins, simulating a benign bone cyst. MRI best documents the multilocular cystic nature of the lesion and the so-called fluid level sign. T1-weighted MRI shows heterogeneous low signal intensity, and T2-weighted images show high signal intensity with several cystic foci, fluid levels and an extra-skeletal extension of the tumor, similar to an aneurysmal cyst, but with irregular walls, septae, and nodular and solid components.
CRITERIA FOR DIAGNOSIS OF TELANGIECTATIC OSTEOSARCOMA:
The criteria for the diagnosing telangiectatic osteosarcoma include:
The high level of alkaline phosphatase frequently seen in osteosarcoma is not a feature of telangiectatic osteosarcoma.
Patients with telangiectatic osteosarcoma receive neo-adjuvant chemotherapy and, when possible, limb-sparing surgery. The extent of surgery which depends on the size, the location and response to the neoadjuvant therapy. Adjuvant chemotherapy can offer some advantage if metastatic disease is present.
Chemotherapeutic protocols for telangiectatic osteosarcoma are similar to those of conventional osteosarcoma. Patients will have two to six cycles of chemotherapy administered before surgery. The common chemotherapeutic agents used include cisplatin, carboplatin, methotrexate, doxorubicin, and ifosfamide. Among these, at least two agents need inclusion in a dual-drug therapy regimen. The effect of chemotherapy on telangiectatic osteosarcoma must undergo reassessment.
Telangiectatic osteosarcoma usually shows a better response to chemotherapy than conventional osteosarcoma. Survival rates with current chemotherapy protocols are within the range of 65% after 5 years. The pattern of metastatic spread of telangiectatic osteosarcoma is similar to that seen in conventional osteosarcoma.
Tumor necrosis greater than 95% is considered one of the most important prognostic factors. Additionally, uninvolved neurovascular bundles and soft tissue and bone resection margins are essential for a favorable prognosis.
Telangiectatic osteosarcoma is a rare and aggressive variant of osteosarcoma with distinctive radiological and pathological features. It poses diagnostic difficulties mainly with aneurysmal bone cyst. Distinguishing between these two entities is vital since their management and prognosis differ significantly. Telangiectatic osteosarcoma is ideally managed by an interprofessional team that consists of orthopedists, oncologists, radiologists, pathologists, pharmacists, and specialty care nurses. Pharmacists review chemotherapeutic regimens, check for drug-drug interactions, and provide patient and family education. Specialty care oncology nurses administer chemotherapy, educate patients and their families, monitor for side effects, and provided feedback on the patient's condition to the team. [Level 5]
|||Sangle NA,Layfield LJ, Telangiectatic osteosarcoma. Archives of pathology [PubMed PMID: 22540307]|
|||Ilaslan H,Sundaram M,Unni KK,Shives TC, Primary vertebral osteosarcoma: imaging findings. Radiology. 2004 Mar [PubMed PMID: 14749514]|
|||Mirra JM,Fain JS,Ward WG,Eckardt JJ,Eilber F,Rosen G, Extraskeletal telangiectatic osteosarcoma. Cancer. 1993 May 15; [PubMed PMID: 8490830]|
|||Roessner A,Hobik HP,Immenkamp M,Grundmann E, Ultrastructure of telangiectatic osteosarcoma. Journal of cancer research and clinical oncology. 1979 Oct [PubMed PMID: 293331]|
|||Metcalf DJ,Nightingale TD,Zenner HL,Lui-Roberts WW,Cutler DF, Formation and function of Weibel-Palade bodies. Journal of cell science. 2008 Jan 1 [PubMed PMID: 18096688]|
|||Fletcher JA,Gebhardt MC,Kozakewich HP, Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes. Cancer genetics and cytogenetics. 1994 Oct [PubMed PMID: 7923089]|
|||Hoogerwerf WA,Hawkins AL,Perlman EJ,Griffin CA, Chromosome analysis of nine osteosarcomas. Genes, chromosomes & cancer. 1994 Feb [PubMed PMID: 7513549]|
|||Zielenska M,Marrano P,Thorner P,Pei J,Beheshti B,Ho M,Bayani J,Liu Y,Sun BC,Squire JA,Hao XS, High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenetic and genome research. 2004 [PubMed PMID: 15305059]|
|||Huvos AG,Rosen G,Bretsky SS,Butler A, Telangiectatic osteogenic sarcoma: a clinicopathologic study of 124 patients. Cancer. 1982 Apr 15 [PubMed PMID: 6950802]|
|||Weiss A,Khoury JD,Hoffer FA,Wu J,Billups CA,Heck RK,Quintana J,Poe D,Rao BN,Daw NC, Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Cancer. 2007 Apr 15 [PubMed PMID: 17351949]|
|||Papagelopoulos PJ,Mavrogenis AF,Savvidou OD,Benetos IS,Galanis EC,Soucacos PN, Pathological fractures in primary bone sarcomas. Injury. 2008 Apr; [PubMed PMID: 18061185]|
|||Kunze B,Bürkle S,Kluba T, Multifocal osteosarcoma in childhood. La Chirurgia degli organi di movimento. 2009 May; [PubMed PMID: 19711159]|
|||Zeitoun R,Shokry AM,Ahmed Khaleel S,Mogahed SM, Osteosarcoma subtypes: Magnetic resonance and quantitative diffusion weighted imaging criteria. Journal of the Egyptian National Cancer Institute. 2018 Mar; [PubMed PMID: 29429892]|
|||Murphey MD,wan Jaovisidha S,Temple HT,Gannon FH,Jelinek JS,Malawer MM, Telangiectatic osteosarcoma: radiologic-pathologic comparison. Radiology. 2003 Nov [PubMed PMID: 14512511]|
|||Liu JJ,Liu S,Wang JG,Zhu W,Hua YQ,Sun W,Cai ZD, Telangiectatic osteosarcoma: a review of literature. OncoTargets and therapy. 2013 [PubMed PMID: 23745051]|
|||Bacci G,Ferrari S,Ruggieri P,Biagini R,Fabbri N,Campanacci L,Bacchini P,Longhi A,Forni C,Bertoni F, Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. Acta orthopaedica Scandinavica. 2001 Apr; [PubMed PMID: 11372948]|
|||Basaran M,Bavbek ES,Saglam S,Eralp L,Sakar B,Atalar AC,Bilgic B,Ozger H,Onat H, A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007 [PubMed PMID: 18185020]|
|||Sandberg AA,Bridge JA, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer genetics and cytogenetics. 2003 Aug; [PubMed PMID: 12885459]|
|||Khuu H,Moore D,Young S,Jaffe KA,Siegal GP, Examination of tumor and tumor-like conditions of bone. Annals of diagnostic pathology. 1999 Dec [PubMed PMID: 10594288]|